ABSTRACT Purpose
Introduction
The term Southeast Asia was first used to define 1 "War Theatre" during the Second World War. As such, unlike some other regional descriptions, it is not a term with long or resonant history. Southeast Asia is a regional intergovernmental organization of 10 countries across Southeast Asia and its member countries are Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Burma, Philippines, Singapore, Thailand, and Vietnam. Southeast Asia was initially formed by the leaders of Indonesia, Philippines, Singapore, Thailand, and Malaysia following the signing of the Southeast Asia declaration on August 8, 1967 . Later remaining countries joined. Southeast Asia also adopted a written constitution known as the Southeast Asia charter in 2007. This charter established the Southeast Asia group as a legal entity creating permanent representation for its members at its secretariat in Jakarta, Indonesia and committed member heads of state to twice-yearly meetings.
Among the 10 Southeast Asian countries for the consideration of generic market, five countries are taken into study to estimate the pharmaceutical pricing nature. There is a larger scope for the growth of pharmaceutical market in those five countries. Indonesia is the largest pharmaceutical markets in the South-East Asian region followed by Thailand, Philippines, Vietnam, and Malaysia. Pharmaceutical companies in Southeast Asia are viewed as secondary to traditional markets due to their lower purchasing power and overall health system 2 maturity . Demographic and economic indicators are illustrated in Table 1 . PESTEL analysis of all 5 Table 2 indicates that these countries have enormous potential yet pose lot of challenges.
Research Methodology

Healthcare Overview of Southeast Asian countries Indonesia
The entire research is done using secondary data from the published articles, journals, tender documents, websites and business analytical reports available on the internet. Author also approached some industry experts to understand some of the complexities and models whenever required. This research seeks to describe the current status of pricing approach in the Southeast Asian countries. The authors did not formulate any hypothesis and used secondary data during this research.
Indonesia's healthcare system is decentralized and organized on a number of levels including provincial, district and sub district. Each sub-district is served by at least one healthcare centre, run by a doctor and a few sub centers usually by nurses. Most of the centers have mobile service units. The Ministry of Health retains central control of the provisional healthcare, while also determining the National Health Policy and supervising National Health Programs. A public healthcare programme for the poor Jamkesmas was started in the year 2008 replacing the previous Askeskin programme. According to Indonesia's statistics as of 2015, 68% of the population was covered by various health insurance schemes such as Jamkesmas for those on low incomes, Badan Penyelenggara Jaminan Sosial (BPJS) and schemes established by the private health 4 insurance. 
Life expectancy at birth
Medical Procurement system Formularium Nasional (FORNAS)
Ever since January 2014, Indonesia has implemented below mentioned two important reforms in pharmaceutical sector in an attempt to improve medicine procurement system
The new national formulary of medicine containing list of molecules aims to support cost-effective and rational use of medicines
E-Catalogue
Thailand E-catalogue is a transparent system that allows centrally negotiated prices for four respective regions to be made available online. The system allows anyone to view these prices through their website. The e-catalogue implementation has been 6 well appreciated due to its transparency.
Healthcare system in Thailand is an entrepreneurialin nature and works with the assistance of public and private providers'. Public health facilities were rapidly expanded nationwide since 1961 when Thailand launched its first five-year national economic and social development plan. Private hospitals also play a key role in health services; however, they are mostly in urban areas. Health policies for continuous improvements of economic growth and for promoting government during the "cold war" period are major drivers for expansion of 7 public health facilities nationwide.
Healthcare financing in Thailand has a long history of evolution of nearly half a decade until Thailand reached the universal healthcare coverage in 2002. It started from user fee exemption and changed to out of-pocket payment to pre-payment system. Various forms of prepayment systems were introduced and tested in Thailand. These implementations led to huge differences in terms of contribution, public subsidy, benefits and quality of services. outcomes between socio-economic groups remain.
A major driver of inequity is the high cost of accessing and using healthcare services. Philippines has had a national health insurance agency -Phil Health -since 1995 and incrementally increased population coverage, but the limited breadth and depth of coverage has resulted in high-levels of out of pocket payments. In July 2010, a major reform effort aimed at achieving 'universal coverage' was launched, which focused on increasing the number of poor families enrolled in Phil Health, providing a more comprehensive benefits package and reducing or eliminating co-payments.
Attracting and retaining staff in under-served areas is key challenge. Philippines is a major exporter of health workers, yet some rural and poor areas still face critical shortages. Inefficiency in service delivery persists as patient referral system and gate keeping do not work well.
Successive reform efforts in financing, service delivery and regulation have attempted to tackle these and other inefficiencies and inequalities in the health system. But implementation has been challenged by the decentralized environment and the presence of a large private sector, often creating fragmentation and variation in the quality of services across the country. 
Procurement system
Central DOH procurement
Vietnam
Medicines must be registered with the BFAD prior to marketing which issues them with a certificate of product registration. Medicines are commonly sold as Individual units. Government procurement of medicines in Philippines is subject to the Government Procurement Reform act (RA 9184/2003:GPR Act) which stipulates the procedures and methods to be used in the public procurement. All procurements are supposed to be based on competitive bidding except in cases of emergency. Alternative methods came in to force in the procurement, limited source bidding and direct procurement methods are set as alternative methods. When these two procurement methods fail then negotiated procurement comes into effect. The Act also initiated a central electronic system for advertising tenders. The system is popularly known 10 as PHILGEPS.
Since 1992 the procurement of medicines was largely the responsibility of local government units. DOH retained hospitals and some CHDS performed their own public bidding. The DOH, through the Central Office Bids and Awards Committee, undertakes limited central procurement for vertical programs e.g. Tuberculosis and Vitamin A supplementation
The government of Vietnam is clearly committed to universal coverage and has approved a number of important laws relating to health financing and health insurance. In addition to some good healthcare indicators, there are impressive achievements to Vietnam's health financing system, namely a population coverage rate of 60% continuous commitment to state subsidized premium payments and developments in the payment systems.
Vietnam has a mixed delivery system, with the public-sector dominant in the provision of hospital care services. Like a lot of countries, Vietnam has a public system that is based on a pyramid model with four levels. As of Jan 1, 2009, in line with the WTO's commitments, foreign investors have been allowed to establish a wholly owned foreign company to import or export pharmaceutical products and sell their imported products to local licensed distributors. In order to import pharmaceutical products, foreign organizations have to depend on local distributors. In order to procure medicines centralized tender process is the most important part of the pharmaceutical and medical device market. In its most basic form the tender process is a government-organized and run bidding and procurement mechanism that is designed to select drug and device products that are characterized by an optimal balance between high quality on the one end and low pricing on the other. In total, it comprises more than 90% of the drug and medical device market.
Malaysia has made great gain in life expectancy for its people. Between 1970 and 2008, the life expectancy in women increased from 65.6 to 76.4 years, while for men the increase was from 61.6 to 71.6 years. Current life expectancy is more than that of uppermiddle income countries, but below high-income countries. Malaysia is undergoing an epidemiological transition with the causes of mortality shifting from communicable to non-communicable diseases. Most deaths in Malaysia are from non-communicable diseases, with diseases of the circulatory system. Malaysia needs better mortality data since some 13 deaths are not medically certified.
Malaysia's health system is mainly financed through general taxation and revenue collected by the Federal government while the private sector is financed through private health insurance and out-of-pocket payment systems from the consumers. Health expenditure remains below the average for upper middle-income countries. Health expenditure has remained predominantly public spending at 55% of total health expenditure. Malaysia faces the challenge of rising public expectations and increasing health expenditure, as do most middle and upper income countries, prompting the government to consider options for future sustainable financing. The government set out ambitious goals for the health system in its 'Vision for Health'. Through this vision, Malaysia is all set to be a nation of healthy individuals, families and communities through a health system that is equitable, affordable, efficient, technologically appropriate, and environmentally adaptable and consumer friendly. Pharmaceutical market dynamics, growth, channels of business etc., are shown in Table 8 . 
Malaysia
Pharmaceutical Sector overview of Southeast Asian countries Indonesia
The growth of the Indonesian pharmaceutical market will be supported by the government's quest for better healthcare provision and the industry's desire to capitalize on these healthcare initiatives and raising inflation. Compared to its other Asia Pacific neighbors, Indonesia's market is small, especially in terms of per capita spending. The Robust expenditure growth along with rapid growth of population will continue to provide substantial income to companies operating in the country. OTC products are regarded as "preventive" medicines. Therefore, these are popular in Indonesia given the low purchasing power and limited availability of prescription drugs. However, the roll-out of JKN programme could further increase the contribution of prescription drugs especially generic ones when 15 all Indonesians are covered in 2019. Healthcare expenditure and pharma market dynamics is illustrated on Table 9 and Figure 1 . 
Thailand
In 2015 Thailand's Pharmaceutical market reached to 4.465Bn$ making a return to positive growth. Over the 2015-2020 forecast period the pharmaceutical market of Thailand is expected to be at 5% CAGR. The higher value of imported drugs over domestically produced medicines will remain a feature of the Thai Pharmaceutical market over the forecasting period, despite the sizeable counterfeit activity in the country, government preference for generic and domestically produced drugs and the Healthcare economics requirements imposed on patented drugs. During the same period, the imports are expected to grow faster.
The innovative pharmaceutical industry is gravely concerned about recent actions of the Royal Thai Government that have seriously undermined patent protection in the Kingdom of Thailand. The Thai FDA does not have a formal patent linkage system to prevent the regulatory approval of copy versions of pharmaceuticals that are still covered by patent. In recent years, there has been a marked increase in the number of copy products receiving Thai FDA approval while the original product is still under patent. This imposes a significant cost on PHRMA 16 member companies. Healthcare expenditure and pharma market dynamics is illustrated on Table 10 and figure 2. 
Philippines
In 2015 Philippine's Pharmaceutical market reached to 3.17 Bn $, a positive growth. When compared with patent market, the generic drug market is growing rapidly. Due to the bad governance in Philippines, pharmaceutical markets are enjoying profits to a huge extent. Philippines will see stable economic growth due to healthy investment activities and private consumption. Due to the mandating of National Health Insurance for all citizens in Philippines the health infrastructure is expected to grow extensively. Prescription medicines will continue to account for majority of the market with a share of 71%. Foreign companies account for the majority of sales in all therapeutic categories, a part from hospital solutions. Philippines is not a major exporter apart from the herbal medicines. The exports and imports balance is unlikely to change hugely due to the concentration of local markets. Raw materials were imported for the pharmaceutical 10 products in a greater extent. Philippines is planning to cut some of its tariffs for pharmaceutical products and lower those on raw material imports. This move should be popular with the local drug makers, as it will result in lower production costs, though the local sector may also face stiff competition. Healthcare expenditure and pharma market dynamics is illustrated on Table 11 and Figure 3 . Various trends in the international market are set to positively influence the growth of Malaysia's generics sector. An interesting development is that of high-value biogenerics, the production of which requires technically superior knowledge and facilities. As Malaysian companies are already building on the physical and technical infrastructure for pharmaceutical production, the biogenerics sector offers an attractive value proposition because we have the added advantage of being able to source for bioactive compounds from our unrivalled 18 biodiverse natural assets.
Drugs developed by multinationals typically have patents valid for a certain number of years, following which local companies are able to manufacture generics and market them at more affordable prices to hospitals, clinics and pharmacies. While this represents a growing source of income for the local sector, more than two-thirds of Malaysian pharmaceuticals still focus on traditional medicine, based on the country's rich natural resources and knowledge of indigenous communities on their healing properties. Consequently, Malaysia still relies quite heavily on imports to fulfill the need for drugs to treat contemporary diseases such as high cholesterol, diabetes, cardiovascular ailments and cancer. Healthcare expenditure and pharma market dynamics is illustrated on Table 13 and figure 5. 
Patented drugs
This group can be further categorized into · Patented, innovative, essential medicines where no alternative medicine or intervention can provide the same therapeutic outcome sometimes referred to as single source medicines · New medicines protected by patents, but for which alternative therapies are available (such as Tamiflu for the treatment of influenza)
The distinction between the two types is important because it reflects the degree of market power held by the seller and the price elasticity of demand. Demand for single source medicines that are considered essential is likely to be inelastic and 
Generic drugs
Generic or multi-source medicines are not under patent protection and can be produced using the same compounds found in the originator product using the same or a different process. Multi-source pharmaceutical products are pharmaceutically equivalent products that may or may not be therapeutically equivalent. The generic products may not be therapeutically equivalent due to a possibility of change in the process of manufacturing. Under special circumstances, such as a public healthcare emergency, countries are allowed to manufacture patented medicines under the compulsory licenses that are granted by World Trade Organization's (WTO) agreement on trade-related aspects of intellectual property rights.
In general, the absence of patent protection lowers the barrier to entry into the market since it reduces the costing of R&D. Reduced R&D costs enable multiple companies to enter the market resulting in a huge competition. However, the expiry of patents does not mean that barriers to market entry disappear. Buyers may always not be aware of the availability of low priced generic medicines, they may have persuaded by promotional efforts not to change brands, or they may view the generic product as inferior or poor quality.
Branded Off Patented drugs
A complicating issue in the generic market is when well-known branded medicines go off patent and the originator company produces generic versions of its own products and retains the brand name that are recognizable through extensive marketing campaigns. Apparently, when the brand name generic has a larger share of the generic market, the brand name medicine will be more expensive. In addition, a higher market share held by the brand name generic will result in high generic medicine prices among all companies. The market entry of brand name generic medicines, if combined with a large market share for the manufacturer will prevent prices falling to levels reached with more diverse competition. Therefore, by entering both brand and generic segments, large companies can exercise 19 considerable market power.
Government Intervention in Pricing
Government inter vention in pricing is a controversial topic because market economists feel strongly that the market should be left to its own 19 devices.
Price controls on the Manufacturer
These price controls usually take the form of governments restricting medicine prices to the cost of production plus a profit margin. However, accurate cost information from the manufacturer is difficult to obtain.
Reference pricing and Brand Premiums
The reference pricing does not necessarily become the market price for all the medicines in the same therapeutic class but rather a benchmark price. Manufacturers can set higher price than the reference pricing but in doing so they need to compete against equivalent, lower priced medicines. Branded premiums are often used in conjunction with reference pricing. They are used when the third party comes into scene during the co-payment.
Fixed Margins
These margins are a fixed percentage of the wholesale price. Problems include the tendency for pharmacists to negotiate rebates and other discounts directly with the wholesalers that do not get passed on the consumer. In some countries these discounts are illegal.
Capitation systems
The pharmacist is reimbursed with a fixed sum based on the number of patients per year or a fixed fee per prescription. The system's goal is to keep pharmacists from benefiting from either the price or volume of units dispensed.
Eliminating Tariffs and Taxes
The sizeable price increase can occur through the out of supply chain in the form of tariffs and taxes. Though taxation increases revenue in low income countries it leads a negative effect in the Health systems.
Factors influencing Pharmaceutical Prices and Total costs
Multiple factors influence the pharmaceutical prices and total costs. Some of these factors are depicted in the figure 7. The choice of which drug is consumed by a patient to treat a particular condition is largely made by the treating physician. Pharmacists cannot substitute a different branded drug within the same therapeutic category without the physician's permission. Pharmacists can, however, substitute generic equivalents of branded drugs-indeed, they are often mandated to do so. For most patients, the costs of consuming prescription drugs are also shared with insurance plans. Insurers and Pharmacy Benefit Managers ("PBMs") can influence drug choice through the co-payments they charge their members. It is within this context that competition between 20 drug manufacturers occurs.
Regulatory system of the country
Drug regulation is an essential part of any country's National Pharmaceuticals policy. Drug regulation needs to flow from a legislative framework that provides the legal basis for a specialized government agency to interpret, implement and enforce laws. In some Southeast Asian countries, the local Regulatory system does not allow the parental company to enter into the market directly. The distribution should be owned by the local distributors which influence the cost of drugs.
Patent status /Intellectual Property Rights
Intellectual Property Rights (IPRs) have been defined as ideas, inventions and creative expressions on which there is a public willingness to bestow the status of property (IPRs) provide certain exclusive rights to the creators of IP, in order to enable them to reap commercial benefits from their creative efforts or reputation. The purpose of IPR legislation is to protect against unauthorized imitation, copying or 21 deceptive usage of identifying marks.
Patent protection does not last forever in the pharmaceutical sector, patent expiration leads to big loss for the originator. But during the patent protection period the Originator Company enjoy profits in a huge number. After the expiration of patent rights generic drugs will come into flow. They will be available at lower price since the R&D costs do not exist.
Selling Expenses
Selling expenses will be very low when the company has its own marketing and sales team in the country. These expenses will be very high when the company do not operate its own and depends upon the local distributors in the country. Due to this, the retail price will increase without the involvement of the manufacturer.
Reorder Frequency and the Total cost of Purchases
Pharmaceutical acquisition prices are only one part of the total cost of pharmaceutical purchasing, the other components are the costs associated with holding inventory, the costs of operating, the purchasing system and the extra costs incurred when stock outs occur. Although procurement offices typically concern themselves mainly with the pharmaceutical costs, the other cost components may increase the total cost by 50% or more of the acquisition costs. For each country's situation, total purchasing costs can be minimized by choosing the optimal reorder frequency model. The reorder frequency model may differ from one type or class of drug product to another. The central medical store can purchase most of the items required in annual tender. The health centers and hospitals may order at a frequency of one month. Total cost analysis examines stable and variable costs for potential savings.
Visible and Hidden costs
Journal The costs associated with shortages and poor supply performance are not so obvious, hidden costs associated with poor performance by the supplier or the procurement office include · Increased acquisition costs due to emergency procurement, such as when a vital medicine is ordered too late or usage exceeds estimates or the supplier fails to deliver on time · Replacement costs when goods are lost or must be discarded because of poor packaging, improper shipping conditions · Replacement costs for short shipments, incorrect concentrations of liquid preparations, wrong dosage forms and so on · Health and economic costs of stock outs resulting from delay or default in delivery
Unit Prices
In some markets even sole source suppliers may offer discount pricing to the public sector that is not necessarily related to purchase volume to establish or maintain market share or to negotiate with international development entities. The type of procurement method used greatly influences competition among potential suppliers. Good procurement practices directly or indirectly influence the degree of competition and the degree of discounting price available to the health system. Components of Price Build-up of pharma products According the WHO/HAI there are six key components which contribute to the price build-up of medicines. These are as follows:
Manufacturer selling price
The net acquisition cost of the medicine from the manufacturer, reflecting all discounts, rebates or other reductions in price.
Cost, insurance, freight charges (CIF), import tariffs and charges. The cost of importing a finished pharmaceutical product (FPP) or active pharmaceutical ingredient (API) into a country.
Importer margin
It is the margin applied by the importer who procures and receives delivery of imported goods.
Distributor margin
It is the margin applied by wholesalers and subwholesalers to perform the logistical role of storing and subsequently transporting medicine to point of sale.
Retailer margin
It is the margin applied by retailers in the final step of the distribution chain, the point at which medicines are dispensed to patients.
Taxes
The final component of the price build-up that can 22 include both national and regional taxes.
Business Models adopted by Pharma companies in Southeast Asia. An effort is made to elaborate and explain various pricing models in Figure 8 . 
Dynamic pricing model for Southeast Asian countries
After the detailed study and evaluation of the channels of business, business model, pricing structure, considering the local regulations in the select countries, an effort is made to develop a dynamic pricing model as illustrated in figure 9 . 
Limitations of the Study
The current study has its own limitations. The study of pricing strategies and pricing model has been conducted through reference of articles, journals, import data, tenders, books that are published on internet. Author also used the market expertize and contacts to gather information related to the topic. Pricing as a subject is vast and requires lot of resources to have a detailed analysis on this topic. There is lot of scope to further study in depth on each derived model. Philippines is planning to cut some of its tariffs for pharmaceutical products and lower those on raw material imports. This move should be popular with local drug makers, as it will result in lower production costs, though the local sector may also face greater competition due to lower duties. Philippines is trying to follow the footsteps of other Southeast Asian countries as far as the medical tourism is concerned. The prescription of generic products in Malaysian pharma public sector is becoming increasingly popular, indicating a greater willingness to use low cost medicines, but it is the changes in the private sector that remain crucial to market development. The private sector favors patented drugs, as they bring high revenues for healthcare providers, would have also felt the pinch of the economic downturn.
Findings/Observations
In Malaysia, most of the prescription & OTC medicines are imported from foreign countries.
Halal medicines are another area where Malaysia shows growth potential. Government offers to lower healthcare spending which prompted new regulations, will stimulate the generics market. The growth drivers of the Malaysian market comprise of cost containment needs and implementation of the Southeast Asia free trade agreement. The flow of exports is expected to increase, tightening competition and pushing local manufacturers to create competitive advantage. Malaysia's MOH has implemented a generic drug policy in which government hospitals have to prescribe generic drugs when patents for the generic drug expire.
The liberalized environment in Vietnam could cause problems for Vietnam's small drug production sector. Vietnam's regulators faced their greatest challenge with the country's entrance at the WTO at the start of 2007. Foreign enterprises have been given the right to open branches in Vietnam and to import medicines directly although they will still be barred from distributing their products. Vietnam's low per capita health and pharmaceutical expenditure highlights the population's poor access to healthcare for services and low affordability levels for medicines particularly high value drugs. This represents a short-term challenge for pharmaceutical firms, but over the long-term the economic position of Vietnam is going to be strengthened. Vietnam requires firms to conduct domestic clinical trials before marketing approval for all pharmaceuticals that have not been made available in their country of origin for more than five years. From a pharmaceutical firm's perspective, these requirements delay the time to market their and hence the revenue generation will not be up to the mark.
Healthcare spending will be a cost containment target in Thailand. Imports will grow at a CAGR of 7% in the forthcoming days. The political stalemate in Thailand will ultimately hurt economic growth, with the under performance of tourism and export sectors weighing heavily on the economy. On the other hand, the expected longer term economic improvements and the consequent rise in income will have a positive impact on the demand for private health services in the country. US, Germany, Spain, Switzerland, France and UK were major importers in the country. Thailand is one of the expensive country for setting up sales and marketing infrastructure and this could be one of the reason pharma products are sold in high prices comparing to neighboring countries. The heightened intellectual property agreements will be particularly sensitive to Thailand due to its history of compulsory licenses.
CONCLUSION
Companies must embrace strategic product pricings in order to sustain in the globalized world. Price is the best weapon to use in the pharma industry. In order to face stiff competition and to maintain continuous growth, pricing the product is tangled considering all the characteristics which affects them. Business strategies will change from one Industry to another Industry. When it comes to pharmaceutical industry, it should change from country to country. Every company will have its own business strategy to succeed but due to some regulatory issues in some countries, the companies may not implement the same business model globally. Business strategies should not be analogous as there is huge distinction in terms of local regulations. In Indonesia and Vietnam these regulations are very high. So, from the above proposed models Collaboration model accomplish very well for the foreign companies in these countries. This model offers risk mitigation and shared by both the companies proportionately.
Companies with tremendous marketing teams can choose Promotion model when the local distributors do not have essential marketing strategies in order to market the product. However, the distribution will be in the hands of Local distributors. Promotion model suits well in Philippines. New Entrants can adopt Distribution model since the financial risk is with the local distributors. The task of the manufacturer is to supply the products according to the requirement of the distributor. In countries with less trade restrictions like in Malaysia; distribution model plays a key role. The distributor will pay off further risk. Promotional activities also will be looked after by the local distributor. If a pharma company has a deep bondage with the local distributors and is ready to share part of risk, then Participation model is the better option. But the manufacturing company should own a local office to look after the sales and promotional activities. The involvement of distributor is very low in this kind of model. In countries like Thailand where there are lot of complexities, that affects pharmaceutical revenues and hence Participation model is precise.
Choosing a right Business model will fetch revenues hugely in the Southeast Asian pharma sector since the growth of Southeast Asian markets are inclining day-by-day above the expectations of the analysts.
